ASND
Ascendis Pharma A/S
$253.29
-0.60%
2026-08-21
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Key Fundamentals
P/E Ratio
19.26
Forward P/E
23.19
EPS (TTM)
$12.90
ROE
332.7%
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Debt/Equity
183.75
Price/Book
30.15
Beta
0.43
Market Cap
$16.30B
Avg Volume (10D)
597K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$282.15
60D Low
$203.80
Avg Volume
643K
Latest Close
$253.29
Get breakout alerts for ASND
Sign up for Breakout Scanner to receive daily notifications when ASND triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Ascendis Pharma A/S (ASND) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ASND daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ASND operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.